You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLenalidomide
Accession NumberDB00480  (APRD01303)
TypeSmall Molecule
GroupsApproved
DescriptionLenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia] FDA approved on December 27, 2005.
Structure
Thumb
Synonyms
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CC-5013
CDC 501
IMid-1
IMiD3
Revlimid
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RevlimidCapsule5 mgOralCelgene Europe Ltd2007-06-14Not applicableEu
RevlimidCapsule20 mgOralCelgene Europe Ltd2007-06-14Not applicableEu
RevlimidCapsule2.5 mg/1OralCelgene Corporation2012-04-16Not applicableUs
RevlimidCapsule2.5 mgOralCelgene Europe Ltd2007-06-14Not applicableEu
RevlimidCapsule25 mgOralCelgene Inc2008-10-10Not applicableCanada
RevlimidCapsule20 mg/1OralCelgene Corporation2013-06-06Not applicableUs
RevlimidCapsule10 mgOralCelgene Europe Ltd2007-06-14Not applicableEu
RevlimidCapsule5 mgOralCelgene Inc2008-02-19Not applicableCanada
RevlimidCapsule5 mg/1OralCelgene Corporation2005-12-27Not applicableUs
RevlimidCapsule7.5 mgOralCelgene Europe Ltd2007-06-14Not applicableEu
RevlimidCapsule25 mg/1OralCelgene Corporation2006-06-29Not applicableUs
RevlimidCapsule15 mgOralCelgene Europe Ltd2007-06-14Not applicableEu
RevlimidCapsule10 mgOralCelgene Inc2008-02-19Not applicableCanada
RevlimidCapsule10 mg/1OralCelgene Corporation2005-12-27Not applicableUs
RevlimidCapsule2.5 mgOralCelgene Europe Ltd2007-06-14Not applicableEu
RevlimidCapsule20 mgOralCelgene Inc2015-09-28Not applicableCanada
RevlimidCapsule25 mgOralCelgene Europe Ltd2007-06-14Not applicableEu
RevlimidCapsule15 mgOralCelgene Inc2008-10-10Not applicableCanada
RevlimidCapsule15 mg/1OralCelgene Corporation2006-06-29Not applicableUs
RevlimidCapsule5 mgOralCelgene Europe Ltd2007-06-14Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LadevinaNot Available
Lenangio Not Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIF0P408N6V4
CAS number191732-72-6
WeightAverage: 259.2606
Monoisotopic: 259.095691297
Chemical FormulaC13H13N3O3
InChI KeyGOTYRUGSSMKFNF-UHFFFAOYSA-N
InChI
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
IUPAC Name
3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
SMILES
NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Pharmacology
IndicationLenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Structured Indications
PharmacodynamicsLenalidomide, a thalidomide analogue, is an immunomodulatory agent possessing immunomodulatory and antiangiogenic properties. Lenalidomide inhibits the secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide inhibits cell proliferation with varying effectiveness (IC50s) in some but not all cell lines. Lenalidomide is effective in inhibiting growth of Namalwa cells (a human B cell lymphoma cell line with a deletion of one chromosome 5) but is much less effective in inhibiting growth of KG-1 cells (human myeloblastic cell line, also with a deletion of one chromosome 5) and other cell lines without chromosome 5 deletions. Lenalidomide does not prolong the QTc interval.
Mechanism of actionThe mechanism of action of lenalidomide remains to be fully characterized, however it has been demonstrated that lenalidomide inhibits the expression of cyclooxygenase-2 (COX-2), but not COX-1, in vitro. In vivo it induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity
TargetKindPharmacological actionActionsOrganismUniProt ID
Protein cereblonProteinyes
inhibitor
HumanQ96SW2 details
Tumor necrosis factor ligand superfamily member 11Proteinyes
inhibitor
HumanO14788 details
Cadherin-5Proteinunknown
antagonist
HumanP33151 details
Prostaglandin G/H synthase 2Proteinunknown
negative modulator
HumanP35354 details
Related Articles
AbsorptionRapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (Cmax) by 36%. The pharmacokinetic disposition of lenalidomide is linear. Accumulation does not occur following multiple doses.
Volume of distributionNot Available
Protein binding30% protein bound.
Metabolism

Lenalidomide undergoes limited metabolism. Unchanged lenalidomide is the predominant circulating component in humans. Two identified metabolites are hydroxy-lenalidomide and N-acetyl-lenalidomide; each constitutes less than 5% of parent levels in circulation. The cytochrome P450 enzyme system is not involved with the metabolism of lenalidomide.

Route of eliminationElimination is primarily renal. When a single oral dose of 25 mg is given healthy subjects, 90% and 4% of the dose is eliminated in urine and feces, respectively. Hydroxy-lenalidomide and N-acetyl-lenalidomide represent 4.59% and 1.83% of the excreted dose, respectively.
Half lifeHealthy subjects = 3 hours; Multiple myeloma or MDS patients = 3 - 5 hours.
Clearance

The renal clearance of lenalidomide exceeds the glomerular filtration rate.

ToxicityThe most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetaminophenThe serum concentration of Lenalidomide can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Lenalidomide.Approved
AfatinibThe serum concentration of Lenalidomide can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Lenalidomide can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Lenalidomide can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Lenalidomide can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Lenalidomide can be increased when it is combined with Alfentanil.Approved, Illicit
ALT-110The risk or severity of adverse effects can be increased when Lenalidomide is combined with ALT-110.Investigational
AmantadineThe serum concentration of Lenalidomide can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Lenalidomide can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Lenalidomide can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Lenalidomide can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Lenalidomide can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Lenalidomide can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Lenalidomide can be increased when it is combined with Amsacrine.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Lenalidomide.Investigational
AstemizoleThe serum concentration of Lenalidomide can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Lenalidomide can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Lenalidomide can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Lenalidomide can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Lenalidomide can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Lenalidomide can be increased when it is combined with Azithromycin.Approved
BazedoxifeneBazedoxifene may increase the thrombogenic activities of Lenalidomide.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Lenalidomide.Investigational
BenzocaineThe serum concentration of Lenalidomide can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Lenalidomide can be increased when it is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Lenalidomide.Approved, Investigational
BiperidenThe serum concentration of Lenalidomide can be increased when it is combined with Biperiden.Approved
BosutinibThe serum concentration of Lenalidomide can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Lenalidomide can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Lenalidomide can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Lenalidomide can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lenalidomide.Approved
CaffeineThe serum concentration of Lenalidomide can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Lenalidomide can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Lenalidomide can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Lenalidomide can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Lenalidomide can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Lenalidomide can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Lenalidomide can be increased when it is combined with Caspofungin.Approved
CDX-110The risk or severity of adverse effects can be increased when Lenalidomide is combined with CDX-110.Investigational
ChloroquineThe serum concentration of Lenalidomide can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may increase the thrombogenic activities of Lenalidomide.Withdrawn
ChlorpromazineThe serum concentration of Lenalidomide can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Lenalidomide can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Lenalidomide can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Lenalidomide can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Lenalidomide can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Lenalidomide can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Lenalidomide can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Lenalidomide can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Lenalidomide can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Lenalidomide can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of Lenalidomide can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Lenalidomide can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe serum concentration of Lenalidomide can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Clozapine.Approved
CobicistatThe serum concentration of Lenalidomide can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Lenalidomide can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Lenalidomide can be increased when it is combined with Colforsin.Experimental
Conjugated Equine EstrogensConjugated Equine Estrogens may increase the thrombogenic activities of Lenalidomide.Approved
CrizotinibThe serum concentration of Lenalidomide can be increased when it is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Lenalidomide.Approved, Investigational
CyclosporineThe serum concentration of Lenalidomide can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DaclatasvirThe serum concentration of Lenalidomide can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Lenalidomide can be increased when it is combined with Dactinomycin.Approved
Darbepoetin alfaDarbepoetin alfa may increase the thrombogenic activities of Lenalidomide.Approved, Investigational
DasatinibThe serum concentration of Lenalidomide can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Lenalidomide can be decreased when it is combined with Daunorubicin.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Lenalidomide.Approved
DesipramineThe serum concentration of Lenalidomide can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Lenalidomide.Approved
DesloratadineThe serum concentration of Lenalidomide can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneDexamethasone may increase the thrombogenic activities of Lenalidomide.Approved, Investigational, Vet Approved
DexamethasoneThe serum concentration of Lenalidomide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Lenalidomide can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Lenalidomide can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienestrolDienestrol may increase the thrombogenic activities of Lenalidomide.Approved
DiethylstilbestrolDiethylstilbestrol may increase the thrombogenic activities of Lenalidomide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Lenalidomide.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lenalidomide.Approved
DihydroergotamineThe serum concentration of Lenalidomide can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Lenalidomide can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Lenalidomide can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lenalidomide.Approved, Investigational
DoxazosinThe serum concentration of Lenalidomide can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Lenalidomide can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Lenalidomide can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Lenalidomide can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Lenalidomide can be increased when it is combined with Dronedarone.Approved
ElbasvirThe serum concentration of Lenalidomide can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Lenalidomide can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Lenalidomide can be increased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Lenalidomide can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Lenalidomide can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Lenalidomide can be decreased when it is combined with Erythromycin.Approved, Vet Approved
ErythropoietinErythropoietin may increase the thrombogenic activities of Lenalidomide.Approved
EstradiolEstradiol may increase the thrombogenic activities of Lenalidomide.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Lenalidomide can be increased when it is combined with Estramustine.Approved
EstriolEstriol may increase the thrombogenic activities of Lenalidomide.Approved, Vet Approved
EstroneEstrone may increase the thrombogenic activities of Lenalidomide.Approved
Ethinyl EstradiolEthinyl Estradiol may increase the thrombogenic activities of Lenalidomide.Approved
EtoposideThe serum concentration of Lenalidomide can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Lenalidomide can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Lenalidomide can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Lenalidomide can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Lenalidomide can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Lenalidomide can be increased when it is combined with Fidaxomicin.Approved
FingolimodLenalidomide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Lenalidomide can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Lenalidomide can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Lenalidomide can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Lenalidomide can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Lenalidomide can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Lenalidomide can be increased when it is combined with Fluvoxamine.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Lenalidomide is combined with G17DT.Investigational
GefitinibThe serum concentration of Lenalidomide can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinGenistein may increase the thrombogenic activities of Lenalidomide.Investigational
GI-5005The risk or severity of adverse effects can be increased when Lenalidomide is combined with GI-5005.Investigational
GlyburideThe serum concentration of Lenalidomide can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Lenalidomide can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Lenalidomide can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Lenalidomide can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Lenalidomide can be increased when it is combined with Haloperidol.Approved
HexestrolHexestrol may increase the thrombogenic activities of Lenalidomide.Withdrawn
HydrocortisoneThe serum concentration of Lenalidomide can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Lenalidomide can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Lenalidomide can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Lenalidomide can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Lenalidomide can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Lenalidomide can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Lenalidomide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Lenalidomide is combined with INGN 225.Investigational
IsavuconazoniumThe serum concentration of Lenalidomide can be increased when it is combined with Isavuconazonium.Approved, Investigational
ItraconazoleThe serum concentration of Lenalidomide can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Lenalidomide can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Lenalidomide can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Lenalidomide can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Lenalidomide can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Lenalidomide can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Lenalidomide can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Leflunomide.Approved, Investigational
LevofloxacinThe serum concentration of Lenalidomide can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Lenalidomide can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Lenalidomide can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Lenalidomide can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Lenalidomide can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Lenalidomide can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Lenalidomide can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Lenalidomide can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Lenalidomide can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Lenalidomide can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Lenalidomide can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Lenalidomide can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Lenalidomide can be decreased when it is combined with Lumacaftor.Approved
MaprotilineThe serum concentration of Lenalidomide can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Lenalidomide can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Lenalidomide can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Lenalidomide can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Lenalidomide can be increased when it is combined with Meprobamate.Approved, Illicit
MestranolMestranol may increase the thrombogenic activities of Lenalidomide.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Lenalidomide.Withdrawn
MethadoneThe serum concentration of Lenalidomide can be increased when it is combined with Methadone.Approved
MethallenestrilMethallenestril may increase the thrombogenic activities of Lenalidomide.Experimental
Methoxy polyethylene glycol-epoetin betaMethoxy polyethylene glycol-epoetin beta may increase the thrombogenic activities of Lenalidomide.Approved
MetoprololThe serum concentration of Lenalidomide can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Lenalidomide can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Lenalidomide can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Lenalidomide can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Lenalidomide can be decreased when it is combined with Mifepristone.Approved, Investigational
MitomycinThe serum concentration of Lenalidomide can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Lenalidomide can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Lenalidomide can be increased when it is combined with Morphine.Approved, Investigational
NaltrexoneThe serum concentration of Lenalidomide can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Lenalidomide can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Lenalidomide can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Lenalidomide can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Lenalidomide can be increased when it is combined with Neostigmine.Approved, Vet Approved
NicardipineThe serum concentration of Lenalidomide can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Lenalidomide can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Lenalidomide can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Lenalidomide can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Lenalidomide can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Lenalidomide can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe serum concentration of Lenalidomide can be decreased when it is combined with Norethisterone.Approved
OmeprazoleThe serum concentration of Lenalidomide can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Lenalidomide.Approved
P-NitrophenolThe serum concentration of Lenalidomide can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lenalidomide.Approved, Vet Approved
Palmitic AcidThe serum concentration of Lenalidomide can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Lenalidomide can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Lenalidomide can be increased when it is combined with Paroxetine.Approved, Investigational
PerindoprilThe serum concentration of Lenalidomide can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Lenalidomide can be decreased when it is combined with Phenobarbital.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lenalidomide.Approved, Investigational
PimozideThe serum concentration of Lenalidomide can be increased when it is combined with Pimozide.Approved
Platelet Activating FactorThe serum concentration of Lenalidomide can be decreased when it is combined with Platelet Activating Factor.Experimental
Polyestradiol phosphatePolyestradiol phosphate may increase the thrombogenic activities of Lenalidomide.Approved
PonatinibThe serum concentration of Lenalidomide can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Lenalidomide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Lenalidomide can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Lenalidomide can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Lenalidomide can be increased when it is combined with Prednisone.Approved, Vet Approved
ProbenecidThe serum concentration of Lenalidomide can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Lenalidomide can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromestrienePromestriene may increase the thrombogenic activities of Lenalidomide.Investigational
PromethazineThe serum concentration of Lenalidomide can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Lenalidomide can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Lenalidomide can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Lenalidomide can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Lenalidomide can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Lenalidomide can be increased when it is combined with Quinacrine.Approved
QuinestrolQuinestrol may increase the thrombogenic activities of Lenalidomide.Approved
QuinidineThe serum concentration of Lenalidomide can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Lenalidomide can be increased when it is combined with Quinine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Lenalidomide.Approved
RanitidineThe serum concentration of Lenalidomide can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Lenalidomide can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Lenalidomide can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Lenalidomide can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Lenalidomide can be decreased when it is combined with Reserpine.Approved
RifampicinThe serum concentration of Lenalidomide can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Lenalidomide can be increased when it is combined with Rilpivirine.Approved
RitonavirThe serum concentration of Lenalidomide can be decreased when it is combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Lenalidomide.Approved
RolapitantThe serum concentration of Lenalidomide can be increased when it is combined with Rolapitant.Approved
S EquolS Equol may increase the thrombogenic activities of Lenalidomide.Investigational
SaquinavirThe serum concentration of Lenalidomide can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Lenalidomide can be increased when it is combined with Scopolamine.Approved
SecoisolariciresinolSecoisolariciresinol may increase the thrombogenic activities of Lenalidomide.Investigational
SelegilineThe serum concentration of Lenalidomide can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Lenalidomide can be increased when it is combined with Sertraline.Approved
SimeprevirThe serum concentration of Lenalidomide can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Lenalidomide can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Lenalidomide.Approved
SirolimusThe serum concentration of Lenalidomide can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Lenalidomide can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Lenalidomide can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Lenalidomide is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Lenalidomide can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Lenalidomide can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Lenalidomide can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Lenalidomide can be increased when it is combined with Sulfinpyrazone.Approved
SumatriptanThe serum concentration of Lenalidomide can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Lenalidomide can be increased when it is combined with Sunitinib.Approved, Investigational
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may increase the thrombogenic activities of Lenalidomide.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lenalidomide.Approved
TacrineThe serum concentration of Lenalidomide can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Lenalidomide.Approved, Investigational
TacrolimusThe serum concentration of Lenalidomide can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Lenalidomide can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Lenalidomide can be increased when it is combined with Taurocholic Acid.Experimental
TelmisartanThe serum concentration of Lenalidomide can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Lenalidomide can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Lenalidomide can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Lenalidomide can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Lenalidomide can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Lenalidomide can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Lenalidomide is combined with TG4010.Investigational
TiboloneTibolone may increase the thrombogenic activities of Lenalidomide.Approved
TicagrelorThe serum concentration of Lenalidomide can be increased when it is combined with Ticagrelor.Approved
TofacitinibLenalidomide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Lenalidomide can be increased when it is combined with Tolvaptan.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Lenalidomide.Approved, Investigational
TrazodoneThe serum concentration of Lenalidomide can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Lenalidomide can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Lenalidomide can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Lenalidomide can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Lenalidomide can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Lenalidomide can be increased when it is combined with Troleandomycin.Approved
VenlafaxineThe serum concentration of Lenalidomide can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Lenalidomide can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Lenalidomide can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Lenalidomide can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Lenalidomide can be increased when it is combined with Vinorelbine.Approved, Investigational
ZeranolZeranol may increase the thrombogenic activities of Lenalidomide.Vet Approved
ZimelidineThe serum concentration of Lenalidomide can be increased when it is combined with Zimelidine.Withdrawn
Food Interactions
  • When given with a fatty meal, the extent of absorption is reduced.
References
Synthesis Reference

Surya Narayana Devarakonda, Sesha Reddy Yarraguntla, Vamsi Krishna Mudapaka, Rajasekhar Kadaboina, Veerender Murki, Amarendhar Manda, Venkata Rao Badisa, Naresh Vemula, Rama Seshagiri Rao Pulla, Venu Nalivela, “PREPARATION OF LENALIDOMIDE.” U.S. Patent US20110021567, issued January 27, 2011.

US20110021567
General References
  1. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57. [PubMed:15703420 ]
  2. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006 Jul 15;108(2):618-21. Epub 2006 Mar 28. [PubMed:16569772 ]
  3. Anderson KC: Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. [PubMed:16344099 ]
External Links
ATC CodesL04AX04
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (400 KB)
MSDSDownload (225 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9958
Blood Brain Barrier+0.9372
Caco-2 permeable-0.5981
P-glycoprotein substrateSubstrate0.6845
P-glycoprotein inhibitor IInhibitor0.6012
P-glycoprotein inhibitor IINon-inhibitor0.8927
Renal organic cation transporterNon-inhibitor0.726
CYP450 2C9 substrateNon-substrate0.8861
CYP450 2D6 substrateNon-substrate0.7878
CYP450 3A4 substrateSubstrate0.5855
CYP450 1A2 substrateNon-inhibitor0.8746
CYP450 2C9 inhibitorNon-inhibitor0.8405
CYP450 2D6 inhibitorNon-inhibitor0.8806
CYP450 2C19 inhibitorNon-inhibitor0.78
CYP450 3A4 inhibitorNon-inhibitor0.7469
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.843
Ames testNon AMES toxic0.8268
CarcinogenicityNon-carcinogens0.9068
BiodegradationNot ready biodegradable0.9967
Rat acute toxicity2.5145 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9803
hERG inhibition (predictor II)Non-inhibitor0.5098
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Celgene corp
  • Celgene Corporation
Packagers
Dosage forms
FormRouteStrength
CapsuleOral10 mg/1
CapsuleOral10 mg
CapsuleOral15 mg/1
CapsuleOral15 mg
CapsuleOral2.5 mg/1
CapsuleOral2.5 mg
CapsuleOral20 mg
CapsuleOral20 mg/1
CapsuleOral25 mg
CapsuleOral25 mg/1
CapsuleOral5 mg
CapsuleOral5 mg/1
CapsuleOral7.5 mg
Prices
Unit descriptionCostUnit
Revlimid 25 mg capsule411.71USD capsule
Revlimid 15 mg capsule407.7USD capsule
Revlimid 10 mg capsule406.05USD capsule
Revlimid 5 mg capsule388.0USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2342974 No2005-08-162014-02-24Canada
CA2477301 No2009-09-012023-04-13Canada
US5635517 No1999-10-042019-10-04Us
US6045501 No1998-08-282018-08-28Us
US6281230 No1996-07-242016-07-24Us
US6315720 No2000-10-232020-10-23Us
US6555554 No1996-07-242016-07-24Us
US6561976 No1998-08-282018-08-28Us
US6561977 No2000-10-232020-10-23Us
US6755784 No2000-10-232020-10-23Us
US6908432 No1998-08-282018-08-28Us
US7119106 No1996-07-242016-07-24Us
US7189740 No2003-04-112023-04-11Us
US7465800 No2007-04-272027-04-27Us
US7468363 No2003-10-072023-10-07Us
US7855217 No2004-11-242024-11-24Us
US7968569 No2003-10-072023-10-07Us
US8204763 No1998-08-282018-08-28Us
US8288415 No1996-07-242016-07-24Us
US8315886 No2000-10-232020-10-23Us
US8404717 No2003-04-112023-04-11Us
US8530498 No2003-05-152023-05-15Us
US8589188 No1998-08-282018-08-28Us
US8626531 No2000-10-232020-10-23Us
US8648095 No2003-05-152023-05-15Us
US8741929 No2008-03-082028-03-08Us
US9056120 No2003-04-112023-04-11Us
US9101621 No2003-05-152023-05-15Us
US9101622 No2003-05-152023-05-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySoluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/mL.Not Available
logP-0.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.33 mg/mLALOGPS
logP-0.43ALOGPS
logP-0.71ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)11.61ChemAxon
pKa (Strongest Basic)2.31ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.5 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity68.3 m3·mol-1ChemAxon
Polarizability25.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoindoles and derivatives
Sub ClassIsoindolines
Direct ParentIsoindolones
Alternative Parents
Substituents
  • Isoindolone
  • Isoindole
  • Piperidinedione
  • Piperidinone
  • Dicarboximide
  • Delta-lactam
  • 3-aminopiperidine
  • Benzenoid
  • Primary aromatic amine
  • Piperidine
  • Carboxylic acid imide, n-unsubstituted
  • Carboxylic acid imide
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly an...
Gene Name:
CRBN
Uniprot ID:
Q96SW2
Molecular Weight:
50545.375 Da
References
  1. Zhu YX, Kortuem KM, Stewart AK: Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. doi: 10.3109/10428194.2012.728597. Epub 2012 Sep 28. [PubMed:22966948 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tumor necrosis factor receptor superfamily binding
Specific Function:
Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced b...
Gene Name:
TNFSF11
Uniprot ID:
O14788
Molecular Weight:
35477.81 Da
References
  1. Akobeng AK, Stokkers PC: Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351. doi: 10.1002/14651858.CD007351.pub2. [PubMed:19370685 ]
  2. Melchert M, List A: The thalidomide saga. Int J Biochem Cell Biol. 2007;39(7-8):1489-99. Epub 2007 Jan 30. [PubMed:17369076 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor binding
Specific Function:
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-cate...
Gene Name:
CDH5
Uniprot ID:
P33151
Molecular Weight:
87527.715 Da
References
  1. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB: The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009 Mar;77(2):78-86. doi: 10.1016/j.mvr.2008.08.003. Epub 2008 Sep 4. [PubMed:18805433 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
negative modulator
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004 Aug;230(2):81-8. [PubMed:15598423 ]
  2. Zeldis JB, Schafer PH, Bennett BL, Mercurio F, Stirling DI: Potential new therapeutics for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr;30(2):275-81. [PubMed:12720152 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 02:43